Overall systemic events and general symptoms · 9‐ to 14‐year‐old females and males
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events at up to 5‐year · 9‐ to 14‐year‐old females and males
It is very uncertain whether two doses of HPV vaccine with longer interval changes serious adverse events at up to 5‐year compared with two doses of HPV vaccine with shorter interval (very low certainty).
1 finding from 1 review
Mortality at up to 5‐year · 9‐ to 14‐year‐old females and males
1 finding from 1 review
Clinical and harms outcomes* · 9‐ to 14‐year‐old females and males
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Live birth or ongoing pregnancy · women undergoing pituitary suppression in assisted reproduction
Long protocol: administration of GnRHa for two showed no clear difference in live birth and ongoing pregnancies per woman randomised compared with three weeks before stimulation (low certainty).
1 finding from 1 review
Clinical pregnancy rate · women undergoing pituitary suppression in assisted reproduction
Long protocol: administration of GnRHa for two showed no clear difference in clinical pregnancies per woman randomised compared with three weeks before stimulation (low certainty).
1 finding from 1 review
Repetition of SH at post‐intervention · self‐harm in adults
Comparison 2.4: DBT prolonged exposure protocol showed no clear difference in repetition of SH at post‐intervention compared with TAU or another comparator (moderate certainty).
1 finding from 1 review
Change in dry eye symptoms, measured using the OSDI score (ranging from 0 to 100 units, with a reduction in score indicating clinical improvement) at 1‐month (with actual · people with dry eyea
Oral long‐chain omega‐3 PUFAs (ie, EPA and DHA) showed no clear difference in change in dry eye symptoms, measured using the OSDI score (ranging… compared with placebo or no treatment (low certainty).
1 finding from 1 review
Change in ocular surface staining at 1‐month (with actual · people with dry eyea
Oral long‐chain omega‐3 PUFAs (ie, EPA and DHA) showed no clear difference in change in ocular surface staining at 1‐month (with actual compared with placebo or no treatment (low certainty).
1 finding from 1 review
Aqueous tear production · people with dry eyea
Oral long‐chain omega‐3 PUFAs (ie, EPA and DHA) showed no clear difference in change in Schirmer test (aqueous tear production, measured in mm/5… compared with placebo or no treatment (moderate certainty).
1 finding from 1 review
Tear film stability · people with dry eyea
1 finding from 1 review
Change in tear osmolarity (measured in mOsmol/L, with reductions in osmolarity indicating clinical improvement) at 1‐month (with actual · people with dry eyea
Oral long‐chain omega‐3 PUFAs (ie, EPA and DHA) showed no clear difference in change in tear osmolarity (measured in mOsmol/L, with reductions in… compared with placebo or no treatment (low certainty).
1 finding from 1 review
Adverse event: gastrointestinal disorders at 1‐month (with actual · people with dry eyea
1 finding from 1 review
Patient satisfaction · Patients with missing teeth and an atrophic posterior maxilla, with residual bone height between 4 and 9 mm below the maxillary sinus
1 finding from 1 review
Treatment costs · Patients with missing teeth and an atrophic posterior maxilla, with residual bone height between 4 and 9 mm below the maxillary sinus
The review found no eligible studies for this question.
1 finding from 1 review
Treatment costs: no trials reported this outcome (extrapolated by the review authors). Additional costs were associated with the long-implant + augmentation group (extra surgery, biomaterial, barrier, hospitalisation…
0 studies
No studies found
Patient preference · Patients with missing teeth and an atrophic posterior maxilla, with residual bone height between 4 and 9 mm below the maxillary sinus
1 finding from 1 review
Complications (at treated sites) · Patients with missing teeth and an atrophic posterior maxilla, with residual bone height between 4 and 9 mm below the maxillary sinus
Maxillary sinus lift (augmentation) with long implants may leads to higher complications (at treated sites) compared with short implants (5 to 8.5 mm) without sinus augmentation (low certainty).
1 finding from 1 review
Augmentation procedure failure · Patients with missing teeth and an atrophic posterior maxilla, with residual bone height between 4 and 9 mm below the maxillary sinus
1 finding from 1 review
Implant failure · Patients with missing teeth and an atrophic posterior maxilla, with residual bone height between 4 and 9 mm below the maxillary sinus
Maxillary sinus lift (augmentation) with long implants showed no clear difference in implant failure compared with short implants (5 to 8.5 mm) without sinus augmentation (moderate certainty).
1 finding from 1 review
Prosthesis failure · Patients with missing teeth and an atrophic posterior maxilla, with residual bone height between 4 and 9 mm below the maxillary sinus
Maxillary sinus lift (augmentation) with long implants showed no clear difference in prosthesis failure compared with short implants (5 to 8.5 mm) without sinus augmentation (moderate certainty).
1 finding from 1 review